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ABSTRACT  
Background: Follow-up infarct volume (FIV) has been recommended as an early indicator of 
treatment efficacy in acute ischemic stroke patients. Questions remain about the optimal imaging 
approach for FIV measurement. 
Objective: To examine the association of FIV with 90-day mRS and investigate its dependency on 
acquisition time and modality. 
Methods: Data of seven trials were pooled. FIV was assessed on follow-up (12 hours-2 weeks) CT or 
MR. Infarct location was defined as laterality and involvement of the ASPECTS regions. Relative 
quality and strength of multivariable regression models of the association between FIV and functional 
outcome were assessed. Dependency of imaging modality and acquisition time (≤48hours versus 
>48hours) was evaluated. 
Results: Of 1665 included patients, 83% was imaged with CT. Median FIV was 41mL (IQR:14-120). 
Large FIV was associated with worse functional outcome (OR=0.88 [95%CI:0.87-0.89] per 10mL) in 
adjusted analysis. A model including FIV, location, and hemorrhage type best predicted mRS. FIV of 
≥133mL was highly specific for unfavorable outcome. FIV was equally strongly associated with mRS 
for assessment on CT and MR, even though large differences in volume were present (48mL [IQR:15-
131] versus 22mL [IQR:8-71], respectively). Associations of both early and late FIV assessments with 
outcome were similar in strength (ρ=0.60 [95CI:0.56-0.64] and ρ=0.55 [95CI:0.50-0.60], 
respectively).  
Conclusions: In patients with an acute ischemic stroke due to a proximal intracranial occlusion of the 
anterior circulation, FIV is a strong independent predictor of functional outcome and can be assessed 
before 48 hours, and on either CT or MR imaging.  
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INTRODUCTION 
In current trials investigating stroke treatment, efficacy is generally evaluated by assessment of 
functional ability and physical limitations of patients rated on a relatively coarse scale such as the 
modified Rankin Scale (mRS). In the causal chain of acute ischemic stroke, treatments are designed to 
save or preserve brain tissue, which subsequently translates to improved functional outcome. 
Following the positive outcome of the five trials proving the efficacy of endovascular treatment 
(EVT) in patients with anterior circulation acute ischemic stroke due to large vessel occlusion,[1–5] it 
has been advocated that the volume of ischemic tissue injury may serve as an early signal of treatment 
efficacy and consequently as a surrogate endpoint for phase II trials.[6] Indeed, most trials also 
showed benefit of EVT in terms of a smaller infarct volume in patients treated with EVT. Follow-up 
infarct volume (FIV) is a more direct measurement of biological effect of treatment and can be 
measured much earlier than the traditional 90-day functional outcome on the mRS. FIV is therefore 
less likely to be confounded by intervening comorbid illness, rehabilitation therapy, or non-stroke 
related pathology. Using FIV as a surrogate could allow early-phase trials to be completed sooner and 
more efficiently, resulting in lower costs and greater speed of therapeutic development. To that end, a 
strong correlation between the potential surrogate and the clinical endpoint must first be proven. 
Previous studies examining the relation between FIV and functional outcomes have yielded 
inconsistent results and reported varying correlations and conclusions.[7–11] Research on the 
translation of ischemic tissue injury to functional outcome is further complicated by discrepancies in 
FIV assessment using different imaging approaches. For example, MR may provide more accurate 
estimates of tissue outcome parameters compared to CT since it is highly sensitive to ischemic tissue. 
Moreover, the optimal timing of FIV assessment is unclear. Imaging too early may prevent the 
accurate measurement of ischemic lesions that continue to grow.[12] In contrast, FIV assessment on 
late (3-7 days) follow-up imaging might be subject to artificial inflation due to cerebral edema. It is 
currently uncertain what effect these dependencies have on the association of FIV and functional 
outcome.[6]  
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Patient-level data of seven major randomized controlled trials that studied the benefit of EVT in acute 
ischemic stroke provided us with an extensive dataset to examine the association of FIV with 90-day 
mRS. In addition, this dataset allows the investigation of the dependency of FIV assessment on 
acquisition time and modality. 
METHODS 
Trial investigators of ESCAPE, EXTEND-IA, SWIFT PRIME, REVASCAT, MR CLEAN, PISTE 
and THRACE established the Highly Effective Reperfusion Evaluated in Multiple Endovascular 
Stroke Trials (HERMES) collaboration.[1–5,13,14] These seven randomized controlled trials 
investigated the benefit of EVT using second-generation mechanical devices in anterior circulation 
ischemic stroke patients. Design features and inclusion criteria of the contributing trials have been 
described previously.[13–15] Each of the seven trials was approved by a local central medical ethics 
committee and the research boards of all participating centers. Written informed consent was acquired 
from all patients or legal representatives. 
According to the original trial imaging protocols, all participating sites were required to perform 24-
hour follow-up imaging and were free to choose between CT and MR. Participating centers from MR 
CLEAN and THRACE were additionally requested to perform follow-up imaging at 5 days, or at 
hospital discharge. In EXTEND-IA, ESCAPE, SWIFT PRIME, REVASCAT and PISTE, 5-day 
follow-up imaging was at the discretion of the intervention site. We included all patients with follow-
up non-contrast CT (NCCT) or MR done at least 12 hours and up to 2 weeks (336 hours) after stroke 
symptom onset. 
Imaging assessment 
Tissue outcome was assessed on follow-up NCCT or MR. If multiple follow-up scans were available, 
the latest scan was selected for analysis with an upper limit of two weeks after onset. If both NCCT 
and MR were performed, MR was the modality of choice. FIVs were initially outlined using 
previously validated software.[16] Manual adjustment of lesion boundaries was performed by an 
expert neuroradiologist (WvZ, LFB or CBM) when appropriate. Areas with parenchymal hemorrhage 
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(within or adjacent to the infarct), cerebral edema extending into the contralateral hemisphere, and 
those causing ventricular and sulcal effacement were included in the lesion. In case of decompressive 
hemicraniectomy with no available pre-surgery scan, only the ischemic lesion within the theoretical 
boundaries of the skull was included. A consensus reading with 2 neuroradiologists was performed to 
resolve cases with any discrepancies. All imaging assessments were performed blinded to treatment 
assignment, study trial, and clinical findings (apart from baseline imaging to identify and eliminate 
old infarcts from the analysis). FIVs were calculated in milliliters (mL) by multiplying the number of 
voxels of the segmented ischemic lesions with its voxel size. Infarct location was assessed by the 
same neuroradiologists (WvZ, LFB or CBM) and defined by laterality (left or right hemisphere) and 
involvement of the 10 distinct anatomical regions of the Alberta Stroke Program Early CT score 
(ASPECTS) template.[17] In case of MR, ≥20% infarction within an ASPECTS region was classified 
as an infarct positive region. The total follow-up ASPECTS score was calculated. Hemorrhagic 
transformations (HT) were scored according to the anatomical description of the Heidelberg 
Classification.[18] In case of multiple intracranial hemorrhages, all were scored. 
Outcomes 
The primary outcome was the degree of disability as scored on the modified Rankin Scale (mRS) at 
90 days, considered as an ordinal outcome.[19] The mRS is a common measure of patient functional 
outcome after stroke, ranging from 0 (no symptoms) to 6 (death). Dichotomized functional outcomes 
were patients with excellent outcome, defined as mRS 0-1 vs. 2-6; patients with functional 
independence, defined as mRS 0-2 vs. 3-6; and death (mRS 6 vs. 0-5).  
Statistical Analysis 
A detailed description of the statistical analysis plan is provided in the Online-only Supplements. 
Dichotomous variables were presented as proportions while continuous variables were tested for 
normality (Shapiro-Wilk test) and presented as mean ± SD if normally distributed, or as median and 
interquartile range (IQR) if not.  
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All statistical analyses were performed in SAS version 9.4 (SAS Institute, Cary, NC, USA) and R 
version 3.2 (R Foundation for Statistical Computing, Vienna, Austria). P-values were two-sided and 
p<0.05 indicated statistical significance in all analyses. 
Association of FIV and mRS   
The association between FIV and ordinal mRS was estimated with adjusted and unadjusted ordinal 
and binary logistic regression models, and expressed as odds ratios (OR) with 95% confidence 
intervals (CI). For the primary outcome, ordinal logistic regression was performed. For dichotomized 
secondary outcomes, binary logistic regression was employed. All multivariable regression analyses 
included the pre-specified prognostic variables age and baseline National Institute of Health Stroke 
Scale score (NIHSS). Missing variables were included after imputation of the relevant covariate with 
median values of the non-missing data. To account for between-trial variance, we used mixed-effects 
modelling with a random effect for trial incorporated in all regression models.  
Four mixed models were constructed; model A included FIV, model B included FIV and infarct 
location (laterality and ASPECTS involvement), model C included FIV and hemorrhage type, and 
model D included FIV, infarct location, and hemorrhage type. The likelihood function test Akaike’s 
Information Criterion (AIC) was used to determine which model provided the best relative quality, 
where lower AIC values represent a better fitting model to the data.  
Effect of age and baseline NIHSS  
Three-dimensional surface plots were constructed to show the relation between favorable outcome,  
FIV, and the prognostic variables age and baseline NIHSS.  
 
Discriminative power of FIV  
The discriminative capability of FIV to predict dichotomized mRS was assessed by receiver operating 
characteristic (ROC) analysis. This was performed for FIVs assessed on either imaging modality and 
 
 
9 
 
for FIVs assessed on MR only. Thresholds for FIV were calculated for predicting unfavorable 
outcome (mRS 3-6) with specificities of 80, 90, and 95%.   
Dependency on imaging modality and acquisition time 
Outcome characteristics were compared to assess differences in subjects imaged with CT versus MR, 
and in subjects whom had imaging acquired within 48 hours of onset versus after 48 hours (and up to 
two weeks). The Mann–Whitney U test was performed to test for differences in FIV. We selected the 
multivariable regression model that provided the best relative quality, and tested whether the relation 
between FIV and mRS was different among imaging modalities and timing of follow-up image 
acquisition. The strength of association of FIV with mRS per imaging modality and follow-up 
acquisition time was calculated using partial Spearman correlations correcting for age, baseline 
NIHSS, and treatment assignment to control for potential confounding effects of those covariates.  
RESULTS 
Of the 1764 patients, 1690 (95.8%) had follow-up imaging acquired at least 12 hours after stroke 
symptom onset and before 2 weeks. Twenty-five patients were additionally excluded because of poor 
image quality or difficulties precluding accurate lesion determination, leading to a total of 1665 
included patients. These difficulties included; large diffuse hemorrhages (n=12), extreme motion 
artefacts (n=8), diffuse cerebral ischemia (n=2), bihemispheric ischemic lesions (n=2), and incomplete 
image reconstruction (n=1). Baseline characteristics of the total population are presented in Online 
supplementary table S1.  
Among 1665 patients, median age was 68 (IQR 57-76) years, and 781 (46.9%) were female. Median 
baseline NIHSS was 17 (IQR 13-21), 740 (47.9%) had a left sided infarct, 844 (50.7%) were 
randomized to EVT and 1496 (90%) received intravenous thrombolysis. The majority (n=1383; 83%) 
had follow-up NCCT and the remainder MR. Median FIV was 41mL (IQR 14-120mL) and median 
mRS at 90 days was 3 (IQR 2-4), with 651 (39.0%) achieving functional independence (mRS 0-2). 
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Eight-hundred-ninety-four (56%) of the 1598 patients with timing reported had follow-up imaging 
within 48 hours.  
Association of FIV and mRS   
The distribution of FIV per mRS category is depicted in Figure 1, which demonstrates progressively 
larger FIVs with increasing mRS scores (Spearman’s ρ correlation coefficient, 0.58; p<0.001). Results 
of the four multivariable regression models of the association between FIV and mRS, and AICs are 
shown in Table 1.  
Table 1. Association of follow-up infarct volume with ordinal modified Rankin Scale and AICs of the 
multivariable models 
 
Model Odds Ratio for FIV per 10mL 95% CI Likelihood function test (AIC) 
A 0.88 0.87 – 0.89 4842 
B 0.91 0.90 – 0.93 4781 
C 0.88 0.87 – 0.90 4825 
D 0.92 0.90 – 0.94 4775 
Odds ratio’s towards shift in better outcome on modified Rankin Scale 
All multivariable regression models (A – D) included age and National Institutes of Health and Stroke Scale 
score. In addition, Model A included FIV; Model B included FIV and location (laterality and Alberta Stroke 
Program Early CT score); Model C included FIV and hemorrhage type, and Model D included FIV, location and 
hemorrhage type.  
Abbreviations: FIV, follow-up infarct volume; CI, confidence interval; AIC, Akaike’s Information Criterion. 
 
The ORs of each variable within the four multivariable regression models are presented in 
Online supplementary table S2. FIV was independently associated with mRS in addition to age and 
baseline NIHSS (p<0.001 for all three variables across all models). Model D, which includes location 
and hemorrhage type was the superior model with the lowest AIC. This best relative quality was 
principally due to the presence of infarct in the Internal Capsule (OR 0.45; p<0.001) and to a lesser 
extent in the M5 ASPECTS regions (OR 0.77; p=0.042), intraventricular hemorrhage (OR 0.29; 
p=0.002), and hemorrhagic infarct type 2 (OR 0.71; p=0.043). Laterality (p=0.36) was not an 
independent predictor of functional outcome.  
Effect of age and baseline NIHSS 
Three-dimensional surface plots of the effects of age, baseline NIHSS and FIV on the likelihood of 
reaching favorable outcome are depicted in Online supplementary figure 1a and 1b for the total 
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population, and in Online supplementary figure 2a and 2b for patients who had FIV assessed on MR 
imaging only. These figures illustrate the importance of age, and show that even with a small FIV, the 
chance of reaching functional independence is drastically reduced in older patients. Moreover, 
patients can still achieve favorable outcomes despite having stroke-related neurologic deficit at 
baseline.  
The relation between FIV adjusted for pre-specified prognostic variables and estimated probability for 
excellent outcome, favorable outcome, and death is displayed in Online supplementary figure 1c. 
Online supplementary figure 2c shows this relation for MR imaging only.   
Discriminative power of FIV  
Analysis of the ROC to classify between favorable and unfavorable outcome by FIV showed an AUC 
of 0.80. ROC analysis for all dichotomized outcomes are shown in Online supplementary figure 3a for 
the total population, and in Online supplementary figure 3b for FIVs assessed on MR. Thresholds for 
FIV with high specificities for an unfavorable outcome (mRS 3-6) are displayed in Table 2. These 
thresholds indicate that unfavorable outcome is almost inevitable when an infarction exceeds 133mL.. 
Thresholds calculated per imaging modality are presented in Online supplementary table S3. 
Table 2. Follow-up infarct volume thresholds with high specificity for unfavorable outcome (modified 
Rankin Scale score of 3-6) 
 
Specificity  Follow-up infarct volume threshold in mL 95% CI for unfavorable outcome 
95% 133 (92.3%, 97.1%) 
90% 96 (87.0%, 92.5%) 
80% 32 (77.3%, 82.6%) 
Abbreviations: CI, confidence interval 
Dependency on imaging modality and acquisition time 
Outcome characteristics stratified by imaging modality and follow-up acquisition time are presented 
in Online supplementary table S4 and S5. We found significantly lower FIVs in subjects imaged with 
MR (median of 22mL) compared to subjects imaged with CT (median of 48mL) (p<0.001). Also, 
patients who underwent MR had lower 90-days mRS scores and rates of hemorrhagic infarct type 2 
(HI-2), higher reperfusion rates, and shorter time from onset to follow-up imaging. Lower rates of 
hemorrhagic infarct type 1 (HI-1) and remote parenchymal hemorrhage were observed in patients who 
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were imaged with CT. We found that mRS was not significantly different (p=0.28) for patients in 
whom FIV was assessed on CT compared to MR in model D, which incorporated lesion location and 
hemorrhage type as a predictor in addition to age and baseline NIHSS. 
A significant difference in FIV was found between patients who had early versus late follow-up 
imaging, with a median of 32 mL in images acquired up to 48 hours versus 56 mL in those acquired 
past 48 hours (p=0.042). Our results show that the relation between FIV and mRS was not 
significantly different between follow-up acquisition times (p=0.36). 
The strength of correlation between FIV and mRS was moderate and statistically significant with a 
Spearman’s ρ of 0.58 (p<0.0001). The correlations of FIV measurements per imaging modality and 
follow-up acquisition time with mRS are shown in Table 3, and are all similar in strength, ranging 
from a Spearman’s ρ of 0.55 for FIV assessment on imaging after 48 hours to a Spearman’s ρ of 0.60 
for FIV assessment on imaging up to 48 hours. 
Table 3. The strength of association of follow-up infarct volume with functional outcome of the total 
population, and per imaging modality and follow-up acquisition time. 
 
FIV assessment Spearman ρ 95% CI p-value 
Full population 0.58 (0.55-0.62) <0.0001 
CT 0.57 (0.53-0.61) <0.0001 
MR 0.59 (0.51-0.66) <0.0001 
≤48 hours 0.60 (0.56-0.64) <0.0001 
>48 hours 0.55 (0.50-0.60) <0.0001 
Abbreviations: FIV, follow-up infarct volume; CI, confidence interval 
DISCUSSION 
Our analysis of the HERMES dataset shows that FIV is an independent predictor of functional 
outcome in patients with acute ischemic stroke due to a proximal intracranial occlusion of the anterior 
circulation in addition to age and baseline NIHSS. We found a strong association between FIV and 
90-day mRS indicating that it might be suitable as a surrogate biomarker for functional outcome after 
acute ischemic stroke presenting within the 0-6 hour window. 
The relation between FIV and functional outcome was consistent across all models, in which FIV 
proved to be an independent predictor. Addition of lesion location and hemorrhage type increased the 
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predictive value of the models. The negative effect of outcome ASPECTS involvement on functional 
outcome was mainly driven by the influence of the internal capsule and the M5 region. These regions 
may include the corticospinal tract and the motor cortex, which emphasizes the pivotal role of damage 
to these areas in determining functional independence of patients.  
The Stroke Treatment Academy Industry Roundtable (STAIR) IX report questioned the optimal 
imaging modality and timing for FIV assessment.[6] In our study, we observed larger volumes when 
FIV was assessed on CT. This is supposedly because trials, which had stricter inclusion criteria 
towards smaller cores at baseline, routinely performed more MR than others. Despite the fact that we 
observed large differences in FIV between modalities, our model showed that functional outcomes of 
CT and MR assessed patients were similar. This is most likely due to the diluting effect of the infarct 
location on the relation of FIV with functional outcome. What is important is that we demonstrated 
similar correlations with functional outcome for both CT and MR. 
Differences in FIV between early and late follow-up imaging were observed. The reasons for this 
include both lesion growth (evolving ischemia) and the development of infarct-associated vasogenic 
edema, which results in larger appearing infarcts. Our data suggest that FIV assessment on early 
follow-up imaging predicts functional outcome with similar strength as assessment on imaging after 
48 hours. Similar findings were reported in MR CLEAN, in which FIV measured at 24 hours and at 1 
week were compared.[12] 
Several studies have previously assessed the relation between FIV and functional outcome on the 90-
days mRS after proximal anterior circulation stroke.[9,10,20,21] All these studies report that FIV is a 
strong predictor of functional outcome, independent from other known important factors such as age 
and baseline NIHSS. Our study confirms these results in the largest patient-level dataset on EVT to 
date. This unique dataset also allowed us to answer questions on how different imaging approaches 
affected the interaction of FIV and functional outcome. Of note is that once FIV and baseline NIHSS 
were included in our models, infarct laterality was not an independent predictor of outcome, 
suggesting that baseline NIHSS captures most of the stroke lateralization effect. Our results also show 
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that, in cases with HT, hemorrhagic infarct type 2 (HI-2) was a stronger predictor of functional 
outcome than parenchymal hematoma type 2 (PH-2). In contrast, previous studies have reported PH-2 
to be more strongly associated with clinical deterioration because of its space occupying effect.[22,23] 
These conflicting results could possibly be attributed to the fact that most of the mass effect of PH-2 
was captured by FIV in our models, since parenchymal hematomas were considered part of the lesion 
volume, leading to a diminished independent effect. Another explanation might be that PH-2 often 
leads to extensive damage, resulting in leakage of blood into other spaces.[24] Therefore, the 
unfavorable effect of PH-2 may have been captured by intraventricular hemorrhage in our models, 
which in our study is associated with poor clinical outcome.  
This study has some limitations. Follow-up NIHSS, a strong predictor of 90-day mRS, was not 
included in our models, as this was not recorded in most of the trials included in our meta-analysis. 
Secondly, infarct location assessment was restricted to follow-up ASPECTS regions combined with 
lateralization. A more detailed analysis on the location of brain tissue injury may improve the strength 
of the relation between FIV and functional outcome, as this more closely resembles brain 
eloquence.[25] Finally, we compared different populations to assess the optimal imaging modality 
and timing for FIV measurement. As some trials routinely performed more MR imaging than others, 
and had different inclusion criteria, this could have biased our results. However, the distribution of 
patients with MR-based assessments was fairly even across the different trials, minimizing this effect. 
In contrast, as almost all late follow-up imaging were from MR CLEAN and THRACE, this finding is 
heavily confounded by study effect. MR CLEAN had no restrictions with regard to baseline 
parenchymal imaging except for the presence of intracranial hemorrhage. As a consequence, most 
patients with large FIVs on early follow-up imaging were from MR CLEAN. In addition, reperfusion 
rates varied per study, which also contributes to infarct size. In order to fully explore and understand 
the interaction between imaging modality and timing on FIV assessment, comparisons must be 
performed in an intra-patient, rather than an inter-patient design. We strove to overcome this 
limitation by using adjusted partial Spearman correlations to control for potential confounding effects. 
Nevertheless, adequate validation can only be addressed in prospective studies with pre-specified time 
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points for FIV assessment, making this a hypothesis generating study that does not provide level 1 
evidence. 
Our study provides useful estimates of high specificity FIV thresholds that may help to identify 
patients for whom reaching functional independence at 90 days is unlikely, potentially influencing 
patient management after stroke, particularly on decisions taken on disposition. Large differences in 
FIV thresholds with high specificity for unfavorable outcome between CT and MR were revealed. 
Underestimation of infarct size on CT could possibly explain why these thresholds were lower for CT. 
Generally, FIV measurements might be less accurate on CT, as CT is less sensitive to ischemia in the 
early phase as compared to diffusion-weighted MR imaging. A phenomenon like ‘fogging’, where 
regions of cortical ischemia regains a near-normal appearance, might also have contributed to 
underestimation of the infarct size. Despite these large differences, we found that FIV assessed on CT 
offers an association with functional outcome of similar strength compared to MR. This is favorable, 
as CT is currently still cheaper and more widely available in many countries. Furthermore, the 
HERMES data suggest that FIV can be measured as soon as after 12 hours, with the major advantage 
that most patients are still at the intervention hospital, which would minimize loss to follow-up.  
FIV has been suggested as surrogate endpoint in early-phase EVT trials, where the aim is to rapidly 
evaluate direct biological effect of therapy. In order for a potential surrogate endpoint to substitute the 
clinical endpoint, the effect of therapy on that surrogate endpoint must accurately reflect and predict 
the effect on the clinical endpoint.[26] We found a strong association between FIV and 90-day mRS, 
regardless of imaging approach, which is a crucial first step for a potential surrogate endpoint. Future 
studies must examine the full potential of FIV as a surrogate through formal testing of the causal 
chain of treatment to FIV to functional outcome. 
CONCLUSIONS 
In summary, this analysis of HERMES confirms that FIV is a strong independent predictor of 
functional outcome at 90 days in patients with acute ischemic stroke due to a proximal intracranial 
occlusion of the anterior circulation presenting within 6 hours after onset. Our data suggest that FIV 
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might be suitable as a prognostic biomarker for functional outcome in acute ischemic stroke, 
irrespective of imaging modality and time to follow-up imaging. 
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FIGURE LEGENDS 
Figure 1: Follow-up infarct volume (FIV) distribution per modified Rankin Scale score (mRS).  
 
 
